Further, ASBT inhibitors have been shown in both humans and animal models to improve insulin sensitivity in diabetes, which may at least in part be attributed to the induction of gut glucagon-like peptide 112,55,56. The gene discussed is SLC10A2; the disease is diabetes mellitus.